Xarelto® - First Once Daily, One Tablet Oral Anticoagulant
- to Simplify Highly Effective Stroke Prevention in Patients with AF
Stroke causes nearly 10% of all deaths worldwide1. Roughly 20% of all ischaemic strokes and transient ischaemic attacks have a cardiac cause-most commonly atrial fibrillation2.
Notably, Xarelto® (rivaroxaban) has recently been approved for the prevention of stroke in patients with atrial fibrillation; providing both physicians and patients with a manageable, therapeutic, and efficacious anticoagulant regimen.
The efficacy of Xarelto in stroke prevention was demonstrated in a multicenter, randomized, double-blind, placebo-controlled, event-driven trial
of over 14,000 patients with atrial fibrillation from 45 countries the ROCKET AF study (Stroke prevention using the oral direct factor Xa inhibitor rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation)3. In this study, Xarelto was shown to be as effective as warfarin.
Overall rates of major and non-major clinically relevant bleeding were similar in the warfarin and Xarelto treated patients; however, whilst major gastrointestinal bleeding was higher in Xarelto treated patients (3.2% vs. 2.2%), fatal bleeds and bleeding in critical organs were less frequent:
- a 50% reduction in fatal bleeding events (p = 0.003)
- a 33% reduction of intracranial hemorrhage
(p = 0.02)
- a 31% reduction of critical organ bleeding events
(p = 0.007)
The risk of stroke for any individual patient with atrial fibrillation varies greatly. Individual patient risk can be assessed with accumulative risk-scoring systems such as CHADS24 and CHA2DS2-VASc5 - see summary box, next page. ►
Xarelto® Adds Simplicity
to Stroke Prevention
VATspace Video 0:52min